Mandate

Vinge advises Fouriertransform

September 30, 2010

Vinge has advised Fouriertransform AB in connection with its investment in MaxTruck AB pursuant to a directed new share issue. MaxTruck has developed a new model of an electric forklift truck which can rotate in all four directions from a stationary position and also rotate around its own axis.

Fouriertransform is participating in the new share issue together with others parties including the company’s founder and CEO, Conny Lindström. Following the new share issue, Fouriertransform will the second largest individual shareholder.

The electric forklift truck has been in development since 2001 and the prototype was unveiled in October 2009. The truck’s unique manoeuverability entails that it needs considerably less space than conventional forklifts which thus reduces the truck’s travel distance and allows it to make more efficient use of warehouse space.

Fouriertransform is a state-owned venture capital company which invests on an arm’s length basis in innovate companies and other enterprises which can contribute to increasing the competitiveness of the Swedish automotive industry.

Vinge’s team consisted of partner Bo Adrianzon and associate Johan Steen who represented Fouriertransform in the negotiations. Other team members included associates Adam Weissbach (IT law) and Sarah Khalil who participated in the due diligence process.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026